{"filings":[{"id":2106043,"accession_number":"0001193125-26-338020","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2026-08-06T20:11:42+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics Q2 2026 net income $1.5M; cash runway to Q3 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net income of $1.5M ($0.01 basic EPS) vs net loss of $30.5M in Q2 2025; revenue $1.1M, down from $2.8M.","Cash $50.8M expected to fund operations into Q3 2028.","RG6501 (OpRegen) Phase 1/2a 3-year data showed sustained BCVA gains and retinal structure restoration in Cohort 4.","COR1 corneal endothelial cell therapy program advanced to in-vivo animal testing; initial data expected in 2026.","Established Scientific Advisory Board with Joachim Fruebis, PhD as founding member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1028319,"accession_number":"0001193125-26-269557","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2026-06-12T20:32:03+00:00","items":["5.07","8.01"],"status":"ready","headline":"Lineage withdraws CIRM grant application for OPC1 SCI trial; annual meeting results disclosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Withdrew CIRM CLIN2 grant application for OPC1 after receiving comments; says DOSED clinical study unaffected.","Shareholders elected all seven director nominees, including Michael Mulroy, Dipti Amin, and Deborah Andrews.","Ratified Baker Tilly as auditor for FY2026 (163.8M for, 0.7M against) and approved advisory say-on-pay (88.3M for, 2.6M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40404,"accession_number":"0001193125-26-219421","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2026-05-12T20:10:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Q1 2026 net loss $4.8M; cash $53.4M; new COR1 program launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.8M ($0.02 basic/$0.03 diluted EPS) vs $4.1M loss in Q1 2025.","Revenue $1.7M (+$0.2M YoY) driven by new WDI collaboration.","Cash & marketable securities $53.4M; expected to fund ops into Q2 2028.","Launched COR1 corneal endothelial cell therapy; second OPC1 spinal cord patient dosed.","First AlloSCOPE 5D milestone achieved; Joachim Fruebis appointed founding SAB member."],"consensus_eps_estimate":-0.0204,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":1725000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115286,"accession_number":"0001193125-26-101167","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics files prospectus supplement for up to $60M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offers up to $60,000,000 of common shares in at-the-market offering through B. Riley Securities.","Prior sales under the same shelf registration total $22,583,664 in aggregate gross proceeds.","Prospectus supplement dated March 11, 2026 supplements shelf registration effective May 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115285,"accession_number":"0001193125-26-093948","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Q4 net income $0.9M, full-year loss $63.5M; cash runway into Q2 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $6.6M (up from $2.9M YoY); net income $0.9M ($0.004 EPS) vs net loss $3.3M ($0.02 loss) in Q4 2024.","Full-year 2025 net loss $63.5M ($0.28/share) vs $18.6M ($0.09/share) in 2024; driven by non-cash warrant remeasurement ($37.9M) and VAC impairment ($14.8M).","Cash $55.8M at Dec 31, 2025; plus $5.4M from warrant exercises in March 2026; expected to support operations into Q2 2028.","Achieved first milestone under Roche/Genentech collaboration for OpRegen; 36-month Phase 1/2a data shows sustained visual acuity gains.","Launched Type 1 diabetes research initiative; treated first chronic SCI patient in OPC1 DOSED study with no safety events at 180 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131697,"accession_number":"0001193125-25-302552","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lineage withdraws CIRM grant app for OPC1; plans resubmission Jan 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Withdrew CIRM CLIN2 grant application on Nov 28 after receiving CIRM comments on Nov 24.","No content deficiencies identified; intends to submit revised application in next CIRM cycle (Jan 2026).","Withdrawal does not impact ongoing DOSED clinical study of OPC1 for spinal cord injury."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131696,"accession_number":"0001193125-25-291979","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lineage achieves first OpRegen milestone under Roche deal; $5M payment triggered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First development milestone under Roche Agreement for OpRegen (RG6501) achieved; $5M payment triggered.","Payment expected within 30 days; net proceeds after ~24.1% to Israel Innovation Authority and ~21.5% to Hadasit.","OpRegen is being evaluated in Phase 2a GAlette trial for geographic atrophy secondary to AMD.","Milestone based on manufacturing and clinical advancements in the OpRegen cell therapy program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131695,"accession_number":"0001193125-25-276249","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lineage Cell Therapeutics sells 12M shares at $1.75 to Janus Henderson, grossing $21M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 12,000,000 common shares at $1.75 per share to Janus Henderson Investors in a block transaction.","Gross proceeds of $21 million before fees and expenses; net proceeds not disclosed.","Transaction executed under the company's existing at-the-market offering program.","Shares trade on NYSE American under ticker LCTX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131694,"accession_number":"0001193125-25-269534","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Q3 net loss widens to $29.8M on warrant remeasurement; cash $40.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.8M ($0.13/sh) vs $3.0M ($0.02) in Q3 2024; includes $26.6M non-cash warrant remeasurement.","Revenue $3.7M, down ~$0.1M YoY; cash $40.5M expected to fund ops into Q2 2027.","Entered collaboration with William Demant Invest for ReSonance (ANP1); up to $12M development funding.","Positive 36-month OpRegen (RG6501) data in dry AMD presented at CTS 2025.","First chronic SCI participant dosed in OPC1 DOSED study; no safety events at 60 days."],"consensus_eps_estimate":-0.0262,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":7948000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148269,"accession_number":"0000950170-25-111319","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics enters collaboration with WDI for hearing loss program; up to $12M funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Multi-year research collaboration with William Demant Invest 2 Aps to advance ReSonance (ANPI) preclinical program for hearing loss.","WDI will fund up to $12 million in research costs over the approximate three-year term.","Objective: complete preclinical phase to achieve readiness for potential human clinical trials.","IP: jointly owned project results; each party retains background IP and platform technology.","If a party abandons, the continuing party may purchase the abandoning party's IP interest in the project."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148268,"accession_number":"0000950170-25-107314","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Q2 net loss widens to $30.5M on $14.8M impairment; OpRegen 36-mo data positive, cash runway into Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $2.8M (+$1.4M YoY); net loss $30.5M ($0.13/sh) vs $5.8M ($0.03) YoY.","Cash $42.3M as of June 30, 2025; expected to fund operations into Q1 2027.","OpRegen: 36-month data shows mean BCVA +6.2 letters (n=10); +9.0 letters in extensive coverage (n=5).","Manufacturing milestone: cGMP production demonstrated for two candidates from cell bank system, scalable to millions of doses.","OPC1: first chronic SCI patient treated in DOSED study using novel delivery system."],"consensus_eps_estimate":-0.0277,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":4267000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148267,"accession_number":"0000950170-25-093007","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 19.5M share increase to 2021 Equity Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment increasing common shares reserved under 2021 Equity Plan by 19,500,000.","All seven director nominees elected: Mulroy, Amin, Andrews, Russell, Bradsher, Culley, Jayasuriya.","Ratification of Baker Tilly as auditor for FY2025 received ~159M votes for, ~912K against.","Advisory say-on-pay approved with ~96M votes for, ~3.8M against, ~612K abstentions.","EIP Amendment approved with ~88.6M for, ~11.6M against, ~351K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167040,"accession_number":"0000950170-25-088738","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lineage reports OpRegen 36-month data: +9 ETDRS letters in extensive-coverage GA patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean BCVA gain of +6.2 letters (n=10) persisting through 36 months vs. +5.5 at 24 months.","Patients with extensive bleb coverage (n=5) showed mean +9.0 letters at 36 months vs. +7.4 at 24 months.","Retinal structure improvements (RPEDC, ELM) on OCT sustained in treated eyes; untreated fellow eyes declined.","Phase 2a GAlette study enrolling (NCT05626114) testing proprietary surgical delivery devices.","CEO states data challenges view that GA causes irreversible damage; effects durable after single injection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167039,"accession_number":"0000950170-25-083866","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics appoints Baker Tilly as auditor after Moss Adams merger","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Moss Adams merged with Baker Tilly effective June 3, 2025; Moss Adams resigned as auditor.","Audit Committee approved Baker Tilly as successor for fiscal year ending Dec 31, 2025.","No disagreements or reportable events occurred during the past two fiscal years or interim period.","Moss Adams' 2024 audit report was unqualified and contained no adverse opinion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167038,"accession_number":"0000950170-25-070337","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics Q1 2025 net loss narrows to $4.1M; cash runway into Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable of $4.1M ($0.02/shr) vs $6.5M ($0.04/shr) in Q1 2024; revenue $1.5M (flat YoY).","Cash and marketable securities of $47.9M as of Mar 31, 2025 expected to fund operations into Q1 2027.","OpRegen 36-month data to be presented June 21 at CTS 2025; OPC1 DOSED study initiated Feb 2025 for spinal cord injury.","3rd Annual SCI Investor Symposium announced with Christopher & Dana Reeve Foundation, virtual starting June 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":1502000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167037,"accession_number":"0000950170-25-061466","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lineage Cell Therapeutics completes cGMP production run for two product candidates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Successfully produced two product candidates using a two-tiered cGMP cell banking system from a single pluripotent cell line.","System uses a genetically-stable master cell bank to generate a working cell bank for final product.","Company states the process could enable millions of doses of consistent, cost-effective allogeneic cell therapy.","Risk factor added: no assurance of consistent cGMP manufacturing at commercial scale or cost-effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184415,"accession_number":"0000950170-25-036278","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell narrows Q4 net loss to $3.3M; OpRegen gets FDA RMAT designation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.3M ($0.02/shr) for Q4 2024 vs $4.8M ($0.03/shr) in Q4 2023; revenue $2.9M vs $2.1M.","Cash of $47.8M at Dec 31, 2024 plus $5.5M from Jan 2025 close; funds operations into Q1 2027.","OpRegen (dry AMD/GA) received FDA RMAT designation; positive 24-month visual acuity data reported.","OPC1 DOSED study initiated Feb 2025 in spinal cord injury; UC San Diego Health first site.","Closed financings for $44M gross proceeds; potential $36M from milestone-linked warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184414,"accession_number":"0000950170-25-009227","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"Lineage closes $6M second tranche of registered direct offering; total $30M received","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second tranche closed Jan 27, 2025; issued 7,894,737 common shares + warrants at $0.76/unit.","Warrants exercisable at $0.91/share from May 21, 2025; expire on OpRegen Phase 2/3 milestone or May 2028.","Potential additional $36M if all warrants exercised; $30M gross proceeds collected to date.","Broadwood Partners (affiliate of board member Neal Bradsher) purchased the second tranche shares.","Shareholders approved issuance at Jan 27 special meeting with 114.1M votes for, 6.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201015,"accession_number":"0000950170-24-129402","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics prices $30M registered direct offering at $0.76/unit with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combined purchase price of $0.76 per share and warrant; $24M from institutional investors, $6M from Broadwood affiliate.","Warrants exercisable at $0.91 for up to ~39.5M shares; expire 3 years from exercise date or 90 days post OpRegen milestone.","Broadwood portion requires shareholder approval under NYSE American rules; closing contingent on satisfaction of conditions.","Net proceeds to fund working capital, R&D, and capital expenditures; potential additional $36M if warrants exercised.","H.C. Wainwright serves as exclusive placement agent with 7% cash fee and 5% warrant coverage at $0.95 exercise price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201014,"accession_number":"0000950170-24-127058","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics Q3 2024 net loss $3.0M, revenue $3.8M; OpRegen gets RMAT designation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.0M ($0.02/sh) vs $7.1M ($0.04/sh) in Q3 2023; revenue $3.8M vs $1.2M.","Cash $32.7M expected to fund operations into Q1 2026.","OpRegen (RG6501) received RMAT designation from FDA for geographic atrophy secondary to AMD.","OPC1 spinal cord injury study start-up activities ongoing; ReSonance preclinical results presented.","Operating expenses $7.6M ($3.2M R&D, $4.4M G&A), down from $7.9M in Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":6631000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217021,"accession_number":"0000950170-24-093947","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics Q2 net loss $5.8M as revenue falls 56% to $1.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Lineage $5.8M ($0.03/share) vs $5.2M prior year; revenue $1.4M vs $3.2M.","Cash and equivalents $38.5M as of June 30; expected to fund operations into Q4 2025.","OpRegen Phase 1/2a data: mean BCVA gain +5.5 letters at 24 months in less advanced GA patients (n=10).","OPC1 spinal cord injury study startup activities ongoing; hosted 2nd Annual SCI Investor Symposium.","Services agreement with Genentech initiated for OpRegen development support, fully funded by Genentech."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":2852000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236784,"accession_number":"0000950170-24-073769","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics dismisses Withum, appoints Moss Adams as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed WithumSmith+Brown effective June 11, 2024.","Engaged Moss Adams as independent auditor for fiscal year ending Dec 31, 2024.","No disagreements or reportable events with former auditor in past two years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236783,"accession_number":"0000950170-24-073072","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics annual meeting: all 9 directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected with 89.8M-90.8M votes for and 1.5M-2.4M withheld.","Ratification of WithumSmithBrown as auditor passed: 128.6M for, 2.4M against.","Advisory say-on-pay approved: 87.8M for, 3.7M against, 0.7M abstentions.","Board amended bylaws effective June 11, 2024, updating advance notice and California code compliance.","Bylaw changes include Rule 14a-19 compliance requirement and electronic meeting provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236782,"accession_number":"0000950170-24-059689","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics files $40M ATM equity offering via B. Riley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement filed May 14, 2024 to sell up to $39,966,424 of common shares at-the-market.","Sales agent is B. Riley Securities, Inc. under agreement dated March 22, 2024.","Shares offered pursuant to effective shelf registration statement (File No. 333-277758).","Legal opinion from Sheppard Mullin on share legality included as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236781,"accession_number":"0000950170-24-056948","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics Q1 2024: rev $1.4M, net loss $6.5M; new Genentech OpRegen deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $1.4M, down from $2.4M YoY; net loss attributable $6.5M ($0.04/sh) vs $4.4M ($0.03/sh).","Cash $43.6M; expected to fund operations into Q3 2025.","New services agreement with Genentech to support OpRegen clinical and manufacturing activities.","OpRegen Phase 1/2a long-term data: mean BCVA gain of 5.5 letters at 24 months in Cohort 4 patients.","OPC1 clinical study start-up underway; received CIRM grant for 2nd Annual SCI Investor Symposium."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":1444000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254397,"accession_number":"0000950170-24-035365","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics enters new ATM facility with B. Riley; FDA delays OPC1 study start","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with B. Riley Securities to sell up to $6.7M in common shares via at-the-market offering; 3% commission.","Terminated prior ATM with Cantor Fitzgerald; prior program sold approximately $6.66M in shares.","FDA review of OPC1 IND for spinal cord injury ongoing; requested not to initiate DOSED study until feedback expected by April 26, 2024.","Initial FDA clinical information request resolved; company aims to open first DOSED study site in Q2 2024.","No change to previously guided timeline for study initiation; no additional activities required to address FDA request."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254396,"accession_number":"0000950170-24-027951","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics reports FY2023 net loss $21.5M; cash runway into Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $8.9M, down 39% from $14.7M in 2022; net loss $21.5M ($0.12/sh).","Q4 2023 net loss $4.8M ($0.03/sh); total operating expenses $8.2M.","Cash $35.5M at 12/31/23 plus $13.8M net from Feb 2024 offering; funds operations into Q3 2025.","OpRegen Phase 2a for dry AMD ongoing with Roche/Genentech; OPC1 IND cleared for spinal cord trial.","Initiated hypoimmune iPSC cell line for neurology under Eterna Therapeutics collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254395,"accession_number":"0001493152-24-006901","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Annual meeting set for June 11, 2024; shareholder proposal deadlines announced","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 annual meeting of shareholders scheduled for June 11, 2024.","Shareholder business or director nominations due by March 15, 2024.","Shareholder proposals for proxy statement inclusion due by March 29, 2024.","Notices directed to Corporate Secretary at Carlsbad, CA address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254394,"accession_number":"0001493152-24-005046","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics enters $14M registered direct offering at $1.04/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale of 13,461,540 common shares at $1.04 each; gross proceeds of $14.0M.","Broadwood Partners (affiliated with director Neal Bradsher) to buy 6,730,770 shares.","Director Don M. Bailey to buy approximately 100,000 shares in the offering.","Closing expected on or about February 8, 2024, subject to customary conditions.","Proceeds to fund clinical trials, R&D, G&A, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271880,"accession_number":"0001493152-23-040057","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell Q3 rev $1.2M, net loss $7.1M; OpRegen Phase 2a enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.2M, down 60% YoY from $3.0M; net loss $7.1M ($0.04/sh) vs $6.1M ($0.04/sh) prior year.","Cash $41.3M, expected to fund operations into Q1 2025.","OpRegen Phase 2a in GA secondary to AMD enrolling under Genentech; new data showed rapid retinal structural improvements within 3 months in 5 patients.","On track to submit OPC1 IND amendment in Q4 2023 for spinal cord injury DOSED study.","Initiated hypoimmune pluripotent cell line development with Eterna Therapeutics; selected B2M deletion, HLA-E insertion, and third undisclosed edit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":6857000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288727,"accession_number":"0001493152-23-031993","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"LCTX shareholders approve share increase and equity plan amendment at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 250M to 450M via articles amendment.","Equity incentive plan share pool increased by 19.5M shares (to 2021 Plan).","All nine director nominees elected; Angus C. Russell received ~19.6M withheld votes.","Ratification of WithumSmithBrown as auditor for FY2023 approved (118.5M for).","Advisory say-on-pay approved with 70.3M votes for; future votes every year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288726,"accession_number":"0001493152-23-027545","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Q2 net loss narrows to $5.2M; OpRegen phase 2a enrolling, OPC1 IND plan in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $5.2M ($0.03/shr) from $6.8M ($0.04/shr) in Q2 2022.","Revenue fell to $3.2M from $4.6M YoY, driven by lower Roche collaboration revenue.","Cash $45.9M; expected to fund operations into Q4 2024.","OpRegen Phase 2a enrolling; FDA meeting response enables OPC1 delivery device IND amendment in Q4.","VAC2 Phase 1 topline: five of eight stable disease; three of eight reached 2-year survival."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":5611000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309365,"accession_number":"0001493152-23-022030","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lineage Cell Therapeutics sets 2023 annual meeting for September 6; proposal deadline July 14","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting scheduled for September 6, 2023.","Shareholder proposals and nominations due by July 14, 2023.","Rule 14a-8 proposals for proxy statement also due July 14."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309364,"accession_number":"0001493152-23-018160","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics updates shelf offering to sell up to $38.9M in common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering up to $38,856,704 of common shares under previously effective Form S-3 registration statement.","Prospectus supplement filed May 18, 2023, updating the Controlled Equity Offering agreement with Cantor Fitzgerald & Co.","Legal opinion from Sheppard, Mullin, Richter & Hampton LLP on share validity included as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309363,"accession_number":"0001493152-23-016388","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics Q1 net loss $4.4M, cash $46.8M; OpRegen phase 2a enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.4M, down 54% YoY from $5.2M due to lower Roche collaboration revenue.","Net loss improved to $4.4M ($0.03/share) from $7.1M ($0.04/share) in Q1 2022.","Cash equivalents and marketable securities $46.8M; expected to fund operations into Q3 2024.","OpRegen Phase 2a for GA secondary to AMD continues enrolling; new sites expected in 2023.","OPC1 granted US patent expiring no earlier than 2040; Type B meeting with FDA planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":2386000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328095,"accession_number":"0001493152-23-007127","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics Q4 net loss $6.4M, revenue $1.9M; cash $57.9M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $6.4M ($0.03/sh), revenue $1.9M; FY2022 net loss $26.3M ($0.15/sh), revenue $14.7M.","Cash and securities $57.9M at Dec 31, 2022; expected to fund planned operations into Q3 2024.","Genentech initiated Phase 2a study of RG6501 (OpRegen) for geographic atrophy; RMAT and pre-IND submitted for OPC1 and VAC2.","Launched two new cell therapy programs for hearing/vision loss; appointed Jill Howe as CFO in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328094,"accession_number":"0001493152-23-002127","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics furnishes corporate investor presentation dated Jan 23, 2023","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation covers Lineage's product candidates and recent business developments.","Filed under Regulation FD; presentation furnished, not filed.","No specific financial or operational updates disclosed in available text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345751,"accession_number":"0001493152-22-031351","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics reports Q3 net loss of $6.1M; appoints Jill Howe as CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Lineage of $6.1M ($0.04/share) vs $7.8M ($0.05/share) in Q3 2021.","Total revenue $3.0M, up from $2.3M YoY, driven by Roche collaboration revenue.","Cash, equivalents, and marketable securities $66.4M as of Sep 30, 2022; expected runway into Q3 2024.","Appointed Jill Howe as CFO effective Nov 14, 2022; she has 20+ years biotech finance experience.","Received notice of allowance for two patents covering directed differentiation methods for RPE and OPC cells."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":12788000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345750,"accession_number":"0001493152-22-029913","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lineage Cell Therapeutics appoints Jill A. Howe as CFO effective Nov 14, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ms. Howe will receive an annual salary of $415,000 and a $50,000 sign-on bonus.","She is eligible for an annual bonus targeted at 40% of salary and granted a stock option for 1,000,000 shares.","Her prior roles include CFO of DTx Pharma, VP Finance at Gossamer Bio (GOSS), and controller at Amplyx.","CEO Brian Culley and Sr. Director Alexandra Hernandez will step down from interim CFO and principal accounting officer roles.","Ms. Howe also serves on boards of Biora Therapeutics (BIOR) and Codagenix Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345749,"accession_number":"0001493152-22-029887","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Lineage Cell Therapeutics settles Asterias merger lawsuit for $10.65M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement of $10.65M funded ~$7.12M by insurers and ~$3.53M by Lineage (cash or shares).","Lineage may issue unregistered common shares under Section 3(a)(10) for its portion.","Settlement subject to Delaware Chancery Court approval; denial would mean continued defense.","Defendants, including Lineage, deny all claims and no admission of liability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362166,"accession_number":"0001493152-22-027295","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K/A","filed_at":"2022-09-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lineage Cell corrects CEO salary to $609k in amended employment agreements","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Corrects CEO Brian Culley's base annual salary from $690,000 to $609,000.","Corrects cash severance payment method: installments for termination without cause/good reason, lump sum only within change-of-control window.","Other terms unchanged: Samuel salary $394,800, Hogge $366,800; bonus targets 55%, 40%, 35% respectively.","Board adopted Executive Performance Incentive Bonus Plan (as originally disclosed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362169,"accession_number":"0001493152-22-026840","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-09-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lineage Cell Therapeutics amends employment agreements and adopts bonus plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["New employment agreements set salaries: CEO $690k, GC $394.8k, SVP $366.8k; bonus targets 55%, 40%, 35% respectively.","Termination benefits enhanced: CEO receives 12 months salary + 100% bonus (18 months + 150% on change of control); others receive 9 months + pro-rata (12 months + 100% on change of control).","New Executive Performance Incentive Bonus Plan adopted; bonuses tied to financial, clinical, and operational goals determined by Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362168,"accession_number":"0001493152-22-022077","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage reports Q2 net loss of $6.8M ($0.04/sh); cash $72M supports through Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.6M, up $4.0M YoY, primarily from Roche collaboration licensing fee.","Net loss attributable to Lineage $6.8M ($0.04/sh) vs $4.8M ($0.03/sh) in Q2 2021.","R&D expenses $3.3M; G&A $5.3M; total operating expenses $8.6M.","Cash, equivalents, and marketable securities $72M; funds operations through Q2 2024.","OpRegen collaboration with Roche advancing; OPC1 results published in J Neurosurg; VAC2 tech transfer complete."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":9790000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362167,"accession_number":"0001493152-22-018802","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-07-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Kevin L. Cook resigns; CEO Brian M. Culley named interim CFO effective July 8, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Kevin L. Cook resigns effective July 8, 2022; resignation not due to any disagreement with Lineage.","CEO Brian M. Culley appointed interim CFO and principal financial officer.","Alexandra Hernandez, Sr. Director of Finance and Controller, named interim principal accounting officer.","Separation agreement provides Cook $318,975 lump sum (9 months base salary) and up to 9 months COBRA coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381682,"accession_number":"0001493152-22-017162","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics holds annual meeting; all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected nine directors: Kingsley, Amin, Andrews, Bailey, Bradsher, Culley, Jayasuriya, Mulroy, Russell.","Ratified WithumSmith+Brown as auditor: 114.8M for, 0.5M against, 1.4M abstain.","Advisory say-on-pay approved: 70.9M for, 1.8M against, 1.8M abstain.","Broker non-votes of 42.2M on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381681,"accession_number":"0001493152-22-013033","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Q1 net loss $7.1M ($0.04/sh); cash $78.1M; pipeline expanded","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Lineage of $7.1M ($0.04/sh) vs $1.4M ($0.01/sh) in Q1 2021.","Total revenues $5.2M, up from $0.4M YoY, driven by $50M Roche upfront licensing fee.","Cash and cash equivalents $78.1M as of March 31, 2022.","Pipeline expanded with two new cell therapy programs: auditory neurons (ANP1) and photoreceptors (PNC1).","VAC2 Phase 1 NSCLC enrollment completed; IND submission for US testing expected 2H 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":5237000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381680,"accession_number":"0001493152-22-012893","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lineage Cell reports OpRegen Phase 1/2a data: 7.6-letter visual gain in Cohort 4 at 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["24 patients treated; no cases of rejection or intraocular inflammation reported.","Cohort 4 (impaired vision) averaged 7.6-letter gain in study eye at Month 12; 25% gained ≥15 letters.","Five Cohort 4 subjects with OpRegen delivered to most/all GA area had average 12.8-letter gain and outer retinal structure improvement.","Majority of AEs were mild (Cohort 4: 93%); most common ocular AEs related to surgical procedure (conjunctival hemorrhage, epiretinal membrane).","OpRegen developed under worldwide collaboration with Roche and Genentech; larger controlled study needed to confirm findings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399670,"accession_number":"0001493152-22-006506","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lineage Cell reports Q4 net loss $0.17/sh; cash $55.7M; Roche deal up to $670M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 net loss $29.0M ($0.17/sh) vs net income $2.0M ($0.01/sh) in Q4 2020; FY 2021 net loss $43.0M ($0.26/sh).","Cash and equivalents $55.7M at Dec 31, 2021; received $50M upfront from Roche/Genentech OpRegen collaboration in Jan 2022.","Roche/Genentech deal for OpRegen (RG6501) worth up to $670M plus double-digit royalties; four dry AMD patients showed retinal restoration.","R&D expenses $24.8M in Q4, driven by $21.0M accrual for future obligations to Israel Innovation Authority and Hadasit.","2022 milestones include new pipeline program announcement, OPC1 manufacturing improvements, and VAC2 IND submission in 2H 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399669,"accession_number":"0001493152-22-004309","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2022-02-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lineage Cell Therapeutics grants 694,424 RSUs tied to Roche collaboration milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RSUs awarded to employees and executive officers; half vest over 4 years, half upon milestone achievement under Roche License Agreement.","Roche deal includes $50M upfront payment and up to $620M in developmental, regulatory, and commercial milestones.","OpRegen cell therapy for ocular disorders (dry AMD with geographic atrophy) is subject of the exclusive worldwide license.","Tiered double-digit royalties on net sales of OpRegen, subject to intellectual property and competitive product offsets.","RSUs granted under 2021 Equity Incentive Plan; continued vesting requires continuous service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418659,"accession_number":"0001493152-21-032109","cik":876343,"company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lineage Cell Therapeutics launches new $64.1M at-the-market equity offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prior $25M ATM program terminated; $14.1M remained unsold.","New ATM allows sale of up to $64,133,000 of common shares via Cantor Fitzgerald.","Shares registered under May 2020 and March 2021 shelf registration statements.","Legal opinion of Cooley LLP filed as Exhibit 5.1; proceeds not specified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":337799175.65384614,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-12-21T23:59:59+00:00|418659"}